-
-
V298968-500mlValproic acid.
-
V121714-100mgVoglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion
-
V121714-25mgVoglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion
-
V121714-500mgVoglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion
-
V121714-50mgVoglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion
-
V121714-5mgVoglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion
-
V345735-100mgVX 702 is an ATP-competitive inhibitor of p38α and p38β MAPK.
-
V345735-10mgVX 702 is an ATP-competitive inhibitor of p38α and p38β MAPK.
-
V345735-25mgVX 702 is an ATP-competitive inhibitor of p38α and p38β MAPK.
-
V345735-50mgVX 702 is an ATP-competitive inhibitor of p38α and p38β MAPK.
-
W124219-1mgWedelolactone, a compound originally extracted from Eclipta alba, has been shown to inhibit caspase-11, which is a key regulator of proinflammatory cytokine IL-1β maturation and pathological apoptosis. Mechanistic studies suggest that caspase-11 is